DNMT3A Regulates Stem Cell Lifespan via Telomerase, Not Just DNA Methylation

Hematopoietic stem cells (HSCs) sustain blood production for a lifetime, carefully balancing self-renewal against differentiation. DNMT3A, a de novo DNA methyltransferase, is the most frequently mutated gene in clonal hematopoiesis (CH) — the age-related expansion of mutant blood stem cell clones that precedes leukemia. Loss of DNMT3A skews HSCs toward self-renewal, but curiously, the resulting DNA methylation changes are modest and poorly correlated with gene expression changes, raising the possibility that DNMT3A functions extend well beyond methylation.

To test this, researchers at Washington University created an allelic series of knock-in mice carrying DNMT3A point mutations (E752A, V712G, R832A) that cripple DNA methylation capacity to varying degrees (0–30% of normal), and crossed these to conditional deletion models. When HSCs expressed only these methylation-dead variants, their clonal self-renewal advantage in serial bone marrow transplantation was dramatically reduced compared to fully null HSCs — and resembled wild-type controls. Complementarily, re-introduction of methylation-impaired DNMT3A variants into DNMT3A-null HSCs was sufficient to restrain aberrant colony-forming activity without restoring global DNA methylation. Together, these experiments establish that DNMT3A's role in restricting HSC self-renewal is largely independent of its enzymatic methyltransferase function.

The study then investigated how DNMT3A-null HSCs escape the normal limits on stem cell lifespan. Strikingly, DNMT3A-null HSCs could be serially transplanted indefinitely — beyond the five rounds at which wild-type HSCs exhaust — without losing engraftment capacity. This mirrors the circumvention of replicative aging. Investigation of telomere biology revealed that DNMT3A-null HSCs have significantly elevated telomerase activity and sustain telomere length across serial transplants, whereas wild-type HSCs progressively shorten their telomeres. This is the first identification of DNMT3A as a regulator of telomerase activity and telomere maintenance in HSCs.

Additionally, DNMT3A-null HSCs showed evidence of altered genome integrity, consistent with a broader role for this protein in maintaining chromosomal stability independent of methylation. The accessory factor DNMT3L — known to form heterotetramers with DNMT3A to catalyze methylation — is not expressed in HSCs, further supporting the idea that canonical methylation complexes are not operative in these cells. Ectopic expression of DNMT3L in HSCs produced different phenotypes than DNMT3A overexpression alone, reinforcing distinct non-canonical roles.

These findings reframe how DNMT3A mutations drive clonal hematopoiesis and potentially leukemogenesis. Rather than acting solely through epigenetic silencing, DNMT3A may normally restrain HSC longevity by limiting telomerase activity — a mechanism that, when disrupted by mutation, grants stem cells a renewable lifespan advantage. This has important implications for understanding aging, clonal dynamics, and therapeutic targeting of CH.